Title : Bortezomib Increases the Cancer Therapeutic Efficacy of Poly(amino acid)-Doxorubicin.

Pub. Date : 2018 Jun 11

PMID : 33445276






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The proteasome inhibitor bortezomib, which is approved clinically and may influence the NFkappaB activity, was thus employed. Bortezomib nuclear factor kappa B subunit 1 Homo sapiens
2 The MTT assay and flow cytometry indicated that it could increase the therapeutic efficacy of poly(amino acid)-doxorubicin, and Western blot results showed that bortezomib and poly(amino acid)-doxorubicin can synergistically diminish NFkappaB expression. Bortezomib nuclear factor kappa B subunit 1 Homo sapiens